



Madhuri Paul



Roberta Buono




Ian Wong

How do statins trigger AML cell death?

David Fruman, PhD


Professor and Chair, Department of Molecular Biology & Biochemistry
Associate Director for Basic Science, CFCCC

Mevalonate pathway is a targetable cancer dependency



D Juarez and DA Fruman, *Trends in Cancer* 2021

Oncogene pathways increase mevalonate demand and supply



D Juarez and DA Fruman, *Trends in Cancer* 2021



Statins in oncology: untapped potential

- Well-tolerated, cost-effective
- Statins can cause apoptosis in cancer cell lines (esp. blood cancers: AML, myeloma)

➤ Leukemia. 1994 Feb;8(2):274-80.

Selective inhibition of primary acute myeloid leukaemia cell growth by lovastatin


A Newman¹, R D Clutterbuck, R L Powles, J L Millar



Roberta Buono


Angela Fleischman
(Heme Biobank)

Pitavastatin enhances cytotoxicity of AML standard-of-care agents



What is the mechanism for statin-mediated apoptosis?

Statins suppress prenylation of signaling proteins




Leukemia (2001) 15, 1398-1407
© 2001 Nature Publishing Group All rights reserved 0887-6924/01 \$15.00
www.nature.com/leu

Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells



Z Xia^{1,3}, MM Tan¹, W Wei-Lynn Wong^{1,2}, J Dimitroulakos^{1,4}, MD Minden^{1,2} and LZ Penn^{1,2}

¹Department of Cellular and Molecular Biology, Ontario Cancer Institute, University Health Network, Toronto; and ²Department of Medical Biophysics, University of Toronto, Toronto, Canada

Statins increase PUMA expression in blood cancer cell lines




J. Scott Lee et al., *Sci. Transl. Med.* 2018; 10(445)



PUMA upregulation is p53-independent



MOLM-14 cell lines and TP53-mutant derivatives





Roberta Buono

MOLM-14 cells and derivatives
provided by Sarah Skuli and Martin Carroll (U-Penn)

GGPP rescues cytotoxicity and PUMA upregulation





PUMA contributes to cytotoxicity but is not the whole story



J. Scott Lee et al., Sci. Transl. Med. 2018; 10(445)


GGPP depletion downregulates mitochondrial gene expression

Mitochondrial-Associated Gene Expression




Bulk RNAseq, 16hr treatment
Pitavastatin vs. PIT+GGPP

Pitavastatin and venetoclax suppress mitochondrial metabolism




Seahorse metabolic flux analysis



Pitavastatin and venetoclax cause loss of membrane potential

16hr treatment: MMP loss measured by TMRE staining



Ian Wong

Mitochondrial Mechanisms of Venetoclax Resistance in AML

Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia

Claudie Bosc  ^{1,2,3}, Estelle Saland ^{1,2,3}, Aurélie Bousard ⁴, Noémie Gadaud ^{1,2,3,5,6}, Marie Sabatier ^{1,2,3}, Guillaume Cognet  ^{1,2,3}, Thomas Farge ^{1,2,3}, Emeline Boet ^{1,2,3}, Mathilde Gotanègre ^{1,2,3}, Nesrine Aroua ^{1,2,3}, Pierre-Luc Mouchel  ^{1,2,3,5,6}, Nathaniel Polley ^{1,2,3}, Clément Larrue ^{1,2,3}, Eléonore Kaphan ^{1,2,3}, Muriel Picard ⁷, Ambrine Sahal ^{1,2,3}, Latifa Jarrou ^{1,2,3}, Marie Tosolini  ¹, Florian Rambow ⁴, Florence Cabon ^{1,2,3}, Nathalie Nicot ⁸, Laura Poillet-Perez ^{1,2,3}, Yujue Wang ⁹, Xiaoyang Su ⁹, Quentin Fovez  ¹⁰, Jérôme Kluza ¹⁰, Rafael José Argüello  ¹¹, Céline Mazzotti ^{1,12}, Hervé Avet-Loiseau ^{1,12}, François Vergez ^{1,2,3,5,6}, Jérôme Tamburini ¹³, Jean-Jacques Fournié ^{1,2}, Ing S. Tiong  ¹⁴, Andrew H. Wei  ¹⁴, Tony Kaoma ¹⁵, Jean-Christophe Marine ⁴, Christian Récher  ^{1,2,3,5,6}, Lucille Stuani  ^{1,2,3,16}, Carine Joffre  ^{1,2,3,16} and Jean-Emmanuel Sarry  ^{1,2,3} 

Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment



Check for updates


Xufeng Chen ^{1,2}, Christina Glytsou ^{1,2}, Hua Zhou ³, Sonali Narang ², Denis E. Reyna ^{4,5,6}, Andrea Lopez ^{4,5,6}, Theodore Sakellaropoulos ^{1,2}, Yixiao Gong ^{1,2,7}, Andreas Kloetgen ^{1,2}, Yoon Sing Yap ^{1,2}, Eric Wang ^{1,2}, Evripidis Gavathiotis ^{4,5,6}, Aristotelis Tsirigos ^{1,2,3}, Raoul Tibes ², and Iannis Aifantis ^{1,2}

Article

Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation

Fangbing Liu ¹, Hasini A. Kalpage  ², Deying Wang ³, Holly Edwards ^{4,5}, Maik Hüttemann  ², Jun Ma ¹, Yongwei Su ^{1,4,5}, Jenna Carter ⁶, Xinyu Li ¹, Lisa Polin ^{4,5}, Juiwanna Kushner ^{4,5}, Sijana H. Dzinic ^{4,5}, Kathryn White ^{4,5}, Guan Wang ^{1,*}  ¹, Jeffrey W. Taub ^{7,8} and Yubin Ge ^{4,5,6,*} 

Working Model: statins disrupt mitochondrial physiology



D Juarez and DA Fruman, *Trends in Cancer* 2021

Next questions

- Can statin cytotoxicity be rescued by restoring mitochondrial function?
(Ubiquinone, α keto-butyrate, aspartate)
- Metabolomics, mito structure, mito mass
- Which GTPases are critical for maintaining mitochondrial health and suppressing PUMA?
 - CRISPR screen for small GTPases, GEFs, GAPs

Next questions

- Can statin cytotoxicity be rescued by restoring mitochondrial function?
(Ubiquinone, α keto-butyrate, aspartate)
- Metabolomics, mito structure, mito mass
- Which GTPases are critical for maintaining mitochondrial health and suppressing PUMA?
 - CRISPR screen for small GTPases, GEFs, GAPs
- Does addition of pitavastatin to VEN regimens prolong survival in *TP53*-mutant AML? Phase 2 in planning stage...



Dr. Elizabeth Brèm

Acknowledgements

Fruman Lab

Roberta Buono, PhD
Madhuri Paul
Ian Wong
Scott Lee, PhD
Dennis Juarez, MD-PhD
Many Bio 199 students



Collaborators

Andy Roberts
Orlando Bueno
Joel Levenson, AbbVie

Sarah Skuli
Martin Carroll, UPENN



LEUKEMIA &
LYMPHOMA
SOCIETY®



UCI Collaborators

Elizabeth Brèm
Susan O'Brien
Angela Fleischman



Cholsoon Jang



Thank You
